Traders should monitor upcoming clinical updates, particularly completion of Phase 1 dose escalation by end-2026. This safety milestone reduces near-term risk and supports potential for future value inflection on efficacy data. Given the company's small market cap ($55M), further clinical progress could drive outsized stock movement.
Price Chart
Executive Summary
Radiopharm Theranostics announced a positive safety review by the Data Safety and Monitoring Committee, allowing advancement of its RAD202 Phase 1 'HEAT' trial to a higher dose level of 130mCi in HER2-positive solid tumors. This progress confirms the therapy's favorable safety profile and keeps the company on track to complete dose escalation by end-2026.
Key Facts
- Radiopharm Theranostics advanced RAD202 to 130mCi dose level in Phase 1 'HEAT' trial for HER2-positive solid tumors.
- Decision follows positive recommendation from Data Safety and Monitoring Committee (DSMC).
- Prior dose level was 75mCi, announced October 1, 2025.
- Phase 1 dose escalation expected to complete by end of 2026.
- Trial ongoing in Australia with no reported safety concerns at current dose.
Financial Impact
Non-dilutive catalyst progression; no direct financial impact yet, but de-risks clinical pathway.
Risk Factors
- Phase 1 safety success does not guarantee efficacy in later stages.
- Next dose level (130mCi) may reveal new safety signals.
- Low liquidity and OTC listing increase volatility risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269961 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers